To date, eight studies have demonstrated antitumor activity of FAP-targeting CAR-T cells in several preclinical models including mesothelioma, lung, mammary, colon, pancreatic cancers (25–32), with a key measure of these studies being the potential for toxicity. This evidence concerns the gene FAP and familial pancreatic carcinoma.